Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

InvestorsWire.com brief · 46d ago · 1 min read · via cnbc.com

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.

The renewed focus on amylin by pharmaceutical giants Eli Lilly and Novo Nordisk is a strategic move to further tackle the lucrative obesity and diabetes markets. Amylin, a peptide hormone co-secreted with insulin from the pancreas, has been recognized for its role in glucose regulation and appetite suppression. The interest in amylin-based therapies comes as the companies seek to build on the success of GLP-1 receptor agonists, a class of drugs that has shown significant promise in treating type 2 diabetes and obesity.

The development of amylin-based drugs represents a diversification of approaches for Lilly and Novo, which have been at the forefront of the GLP-1 receptor agonist market. With the global obesity market expected to continue growing, these companies are positioning themselves to capture a larger share of the market. The amylin pathway offers a complementary mechanism of action to GLP-1 receptor agonists, potentially providing patients with more treatment options and improving outcomes.

Investors should watch for updates on the clinical trials and potential market launches of these new amylin-based therapies. The success of these drugs will depend on their efficacy, safety profile, and how they differentiate from existing treatments. Additionally, the competitive landscape will be influenced by the regulatory environment and the strategies of other pharmaceutical companies seeking to enter the obesity and diabetes markets. As the market continues to evolve, Lilly and Novo's investments in amylin-based therapies will be closely monitored for their potential impact on the companies' financial performance and market share.

Originally reported by cnbc.com. InvestorsWire adds analysis for finance & markets readers.

Originally reported by cnbc.com. InvestorsWire.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily finance & markets signal

More from InvestorsWire.com

Related ventures